The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Precede Bio; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Pamela Atherton
No Relationships to Disclose
 
Karla Ballman
Consulting or Advisory Role - GlaxoSmithKline
Expert Testimony - Janssen
 
Heather Jacene
Consulting or Advisory Role - Luminance Biosciences
Research Funding - Blue Earth Diagnostics (Inst); Boston Scientific (I); Lantheus Medical Imaging (Inst)
Travel, Accommodations, Expenses - Abbott Laboratories (I); Abiomed (I); Biotronik International (I); Medtronic (I)
 
Ronald Chen
Employment - University of Kansas Medical Center
Consulting or Advisory Role - Abbvie; Accuray; Accuray; Astellas Pharma; Bayer; Blue Earth Diagnostics; Genentech; Janssen; Medivation/Astellas; Myovant Sciences; Pfizer; VIR Biotechnology; VIR Biotechnology
Research Funding - Accuray
Travel, Accommodations, Expenses - Reflexion Medical; Telix Pharmaceuticals
 
Atish Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Aptitude Health; Color Genomics; Conexiant; DAVA Oncology; Lantheus Medical Imaging; MDoutlook; Medscape; OncLive; Outcomes4Me; Pfizer; Physicans' Education Resource; Targeted Oncology; Wiley
Consulting or Advisory Role - Astellas Pharma; Bayer; Boundless Bio; Daiichi Sankyo; Janssen Oncology; Johnson & Johnson/Janssen; Novartis; Pfizer; Pfizer; Sanofi/Aventis; Tolmar
Research Funding - Bayer (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); Sumitomo Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Novartis
 
Joshua Lang
Leadership - EOLAS Diagnostics, INC
Consulting or Advisory Role - 4D Pharma; Arvinas; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Gilead Sciences; Janssen; Macrogenics; Pfizer; Pfizer/Astellas; Pfizer/Myovant; Sanofi
Research Funding - Agensys (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.
 
Suzanne Cole
Research Funding - Merck (Inst)
 
Tareq Al Baghdadi
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Cardinal Health
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cardinal Health; Genentech/Roche
 
Young Kwok
No Relationships to Disclose
 
Alan Tan
Honoraria - Aveo; Bristol Myers Squibb Foundation; Exelixis; Merck; Pfizer
Consulting or Advisory Role - Foundation Medicine; Janssen Oncology
Speakers' Bureau - AVEO; bristol myers squibb; Exelixis; Merck; Pfizer
 
Stephanie Berg
Honoraria - Aptitude Health; Curio Science
Consulting or Advisory Role - Eisai; Exelixis; Guardant Health; Natera; Pfizer; Zencor
Travel, Accommodations, Expenses - Exelixis
 
Himisha Beltran
Consulting or Advisory Role - AstraZeneca; Bayer; Daicchi Sankyo; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Michael Morris
Employment - Memorial Sloan-Kettering Cancer Center
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Advancelle; Amgen; ARTbio; Arvinas; Bristol-Myers Squibb; Convergent Therapeutics; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; Isotopia; Lantheus Medical Imaging; Mashup Media; Molecular Partners; Soffinova; Transtherabio; Wren Laboratories; Z-Alpha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Abbvie; APCCC; Memorial Sloan-Kettering Cancer Center
(OPTIONAL) Uncompensated Relationships - Amgen; Bayer; Halda Therapeutics; Janssen Oncology; Novartis
 
Bradley McGregor
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; AVEO; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genmab; Gilead Sciences; Hexagon; Loxo/Lilly; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; Dava Oncology; Mashup Media; MJH Life Sciences; Peerview
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Dendreon; Eisai; EMD Serono; Exelixis; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Xencor
Research Funding - ALX Oncology (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Janux Therapeutics (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Merck (Inst); OncoC4; Pfizer (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Bayer; Janux Therapeutics; Johnson & Johnson/Janssen
Other Relationship - ASCO; Kidney Cancer Association; KidneyCan; Myrovlytis Trust; Winn Foundation
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Jonathan Rosenberg
Honoraria - Astellas Pharma; Merck
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Domain Therapeutics; EMD Serono; Generate Biomedicines; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Samsung Bioepis; Seagen; Summit Therapeutics; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); Bristol-Myers Squibb; Lilly; Pfizer
Patents, Royalties, Other Intellectual Property - Amplification of chromosome 1q23 to predict cancer outcomes (Inst); Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
(OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology; Kalivir Immunotherapeutics
 
Daniel George
Leadership - Capio BioSciences
Stock and Other Ownership Interests - BMS; Pfizer
Honoraria - Astellas Pharma; AstraZeneca; Axess Oncology; Bayer; Candel Therapeutics; Eisai; IDEOlogy Health; Janssen Oncology; Merck; Millennium Medical Publishing; Novartis; OncLive; Pfizer; Sumitomo; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Candel Theraputics; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Novartis; Pfizer; Physicans' Education Resource
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Convergent Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Novartis; Pfizer
 
Toni Choueiri
Leadership - ASCO
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Caris Life Sciences; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES
(OPTIONAL) Uncompensated Relationships - AACR Scientific Advisory Council